Name:
DAPA2 Trial and the Elderly
Description:
DAPA2 Trial and the Elderly
Thumbnail URL:
https://cadmoremediastorage.blob.core.windows.net/064d9595-1a3b-4d21-8a53-b660b2edc65d/thumbnails/064d9595-1a3b-4d21-8a53-b660b2edc65d.jpeg?sv=2019-02-02&sr=c&sig=H7xBpsmgzNREb8go44mvC7lmFt5%2By8Jkp980JgwQBDQ%3D&st=2024-12-21T14%3A15%3A36Z&se=2024-12-21T18%3A20%3A36Z&sp=r
Duration:
T00H03M05S
Embed URL:
https://stream.cadmore.media/player/064d9595-1a3b-4d21-8a53-b660b2edc65d
Content URL:
https://cadmoreoriginalmedia.blob.core.windows.net/064d9595-1a3b-4d21-8a53-b660b2edc65d/18519196.mp3?sv=2019-02-02&sr=c&sig=L28DOippLo0Bu8poO7lXG8SJNi2F4C57m0ZK6GSfzBs%3D&st=2024-12-21T14%3A15%3A36Z&se=2024-12-21T16%3A20%3A36Z&sp=r
Upload Date:
2022-02-28T00:00:00.0000000
Transcript:
Language: EN.
Segment:0 .
>> Practice Impact Extra podcasts are derived from Hurst's the Heart Board Review and other online resources available only through accesscardiology.com. >> [ Music ] We know that sodium glucose cotransporter drugs, the STLT-2 drugs, have really had a significant positive affect on the reduction of CV deaths and hospitalization for heart failure but as always, we want to look at the safety, particularly in the elderly. [ Music ] Dr. Bernie here and welcome to Practice Impact Extra.
I want to review the DAPA2 trial as already published in the New England Journal of Medicine. And I've also provided in the past some podcasts assessing some of the data related to the DAPA2 trial, but I wanted to present some additional outcomes related to safety of Dapagliflozin, particularly in the elderly. I feel that this is really important because the fact is that heart failure is a significant disease in the elderly.
Dapagliflozin is a sodium glucose cotransporter 2. It's an SGLT2 which I believe is a game changer. DAPA2 trial revealed a significant reduction in cardiovascular deaths and hospitalization for heart failure with similar outcomes that you're aware in the diabetic and in the non-diabetic patient. In this follow up analysis, which was presented in November 2019, Dapagliflozin was compared to placebo and looked at the hazards ratio for primary outcomes which we know as cardiovascular deaths, congestive heart failure, hospitalization.
And it was assessed across 4 various age groups. Less than 55. Fifty-five to 64 years. Sixty-five to 74 years and greater than 75 years. And what they found was that then the benefit of Dapa across all the age groups was significant and there was no apparent safety signal. So, what's the take home message here? Patients with heart failure with reduced ejection fraction treated with Dapagliflozin achieved a significant reduction in cardiovascular deaths and heart failure and improved quality of life measures.
The benefit was consistent across the age spectrum in diabetic and non-diabetics without an increase in adverse safety event. I think we need to familiarize ourselves and be fast to put these drugs in our comfort zone. Thanks for joining me and see you next time on Practice Impact Extra. >> We hope you enjoyed this podcast from McGraw-Hill. Subscribers to Access Cardiology have instant access to over 25,000 pages of rich medical content, receive medical updates from trusted experts, and have access to other special features.
To subscribe or learn more, please visit accesscardiology.com.
